Market Overview

Goldman Sachs Upgrades Vertex Pharmaceuticals To Buy

Share:
Related VRTX
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
Benzinga's Bulls And Bears Of The Past Week: Netflix, Intel, Tesla And More

Analysts at Goldman Sachs upgraded Vertex Pharmaceuticals (NASDAQ: VRTX) from Neutral to Buy.

The target price for Vertex Pharmaceuticals has been raised from $109 to $131.

Vertex Pharma shares have gained 16.00% over the past 52 weeks, while the S&P 500 index has surged 20.10% in the same period.

Vertex Pharmaceuticals' shares rose 0.22% to $95.25 in pre-market trading.

Latest Ratings for VRTX

DateFirmActionFromTo
Sep 2017DA DavidsonInitiates Coverage OnBuy
Sep 2017RBC CapitalInitiates Coverage OnOutperform
Jul 2017CitigroupMaintainsBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Goldman SachsUpgrades Analyst Ratings

 

Related Articles (VRTX)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...